PARIS, Jan 30 (Reuters) - Healthcare companies Sanofi
and Regeneron said on Monday that their
Dupixent product had won approval from the European Commission
to treat eosinophilic esophagitis (EoE), which is a condition
that damages the esophagus."This latest approval establishes Dupixent as the only
targeted medicine specifically indicated for eosinophilic
esophagitis in the European Union," said George D. Yancopoulos,
President and Chief Scientific Officer at Regeneron.
s
(Reporting by Sudip Kar-Gupta; Editing by Himani Sarkar)